These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 761177)
1. VP 16-213 (VP 16) and cyclophosphamide in the treatment of primitive lung cancer in phase M 1. Estape J; Milla A; Agusti A; Lloret JS; Palacin A; Soriano E Cancer; 1979 Jan; 43(1):72-7. PubMed ID: 761177 [TBL] [Abstract][Full Text] [Related]
2. VP-16, cyclophosphamide, adriamycin and cis-platinum (V:CAP-I) in patients with metastatic adenocarcinoma of the lung. Eagan RT; Creagan ET; Ingle JN; Rubin J; Frytak S; Kvols LK; Fleming TR Tumori; 1979 Feb; 65(1):105-9. PubMed ID: 442215 [TBL] [Abstract][Full Text] [Related]
3. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study. Goodman GE; Crowley JJ; Blasko JC; Livingston RB; Beck TM; Demattia MD; Bukowski RM J Clin Oncol; 1990 Jan; 8(1):39-47. PubMed ID: 2153194 [TBL] [Abstract][Full Text] [Related]
4. cis-Dichlorodiammineplatinum(II) and VP-16-213: an active induction regimen for small cell carcinoma of the lung. Sierocki JS; Hilaris BS; Hopfan S; Martini N; Barton D; Golbey RB; Wittes RE Cancer Treat Rep; 1979; 63(9-10):1593-7. PubMed ID: 227598 [TBL] [Abstract][Full Text] [Related]
5. Bone marrow morphologic changes after combination chemotherapy including VP-16. Adelstein DJ; Hines JD Cancer; 1985 Aug; 56(3):467-71. PubMed ID: 2988744 [TBL] [Abstract][Full Text] [Related]
6. VP-16-213 and cyclophosphamide in small cell lung cancer: a long-term followup report. Britell JC; Eagan RT; Lee RE Cancer Treat Rep; 1979; 63(11-12):2130-1. PubMed ID: 230899 [No Abstract] [Full Text] [Related]
7. Cyclophosphamide and VP-16-213 with or without cisplatin in squamous cell and small cell lung cancers. Eagan RT; Frytak S; Nichols WC; Ingle JN; Creagan ET; Kvols LK Cancer Treat Rep; 1981; 65(5-6):453-8. PubMed ID: 6263477 [TBL] [Abstract][Full Text] [Related]
8. Lack of potentiation of vincristine-induced neurotoxicity by VP-16-213. Jackson DV; Wells HB; White DR; Muss HB; Richards F; Cooper MR; Stuart JJ; Pope EK; Spurr CL Am J Clin Oncol; 1983 Jun; 6(3):327-30. PubMed ID: 6303106 [TBL] [Abstract][Full Text] [Related]
9. VP-16 plus cyclophosphamide in the treatment of advanced lung cancer. Estape J; Milla A; Agusti A; Sanchez-Lloret J; Santabarbara P; Rozman C Cancer; 1983 Feb; 51(3):385-9. PubMed ID: 6295601 [TBL] [Abstract][Full Text] [Related]
10. Possible enhancement of vincristine neuropathy by VP-16. Thant M; Hawley RJ; Smith MT; Cohen MH; Minna JD; Bunn PA; Ihde DC; West W; Matthews MJ Cancer; 1982 Mar; 49(5):859-64. PubMed ID: 6277454 [TBL] [Abstract][Full Text] [Related]
12. VP-16 and adriamycin in patients with advanced breast cancer. Vaughn CB; Maniscalco-Greb E; Lockhard C; Groshko G; Enochs K; Duffin H; Demitrish M Am J Clin Oncol; 1982 Oct; 5(5):505-9. PubMed ID: 6897491 [TBL] [Abstract][Full Text] [Related]
13. Feasibility of high dose VP 16-213 as single agent or in combination with cyclophosphamide and autologous bone marrow transplantation (ABMT). Mulder NH; Meinesz AF; Sleijfer DT; Postmus PE; De Vries EG; Van der Geest S; Orie JL; Vriesendorp R Neth J Med; 1984; 27(10):389-92. PubMed ID: 6096742 [No Abstract] [Full Text] [Related]
14. [VP 16-213 in combination with endoxan, methotrexate and oncovin as polychemotherapy for bronchogenic carcinoma]. Ryssel HJ; Hasler E; Sonntag RW; Cavalli F; Martin J; Tschopp L; Brunner KW Schweiz Med Wochenschr; 1977 Jul; 107(26):912-5. PubMed ID: 877537 [TBL] [Abstract][Full Text] [Related]
15. Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group. Hong WK; Nicaise C; Lawson R; Maroun JA; Comis R; Speer J; Luedke D; Hurtubise M; Lanzotti V; Goodlow J J Clin Oncol; 1989 Apr; 7(4):450-6. PubMed ID: 2538577 [TBL] [Abstract][Full Text] [Related]
16. VP-16-213 in combination chemotherapy with chest irradiation for small-cell lung cancer: a randomized trial of the Piedmont Oncology Association. Jackson DV; Zekan PJ; Caldwell RD; Slatkoff ML; Harding RW; Case LD; Hopkins JO; Muss HB; Richards F; White DR J Clin Oncol; 1984 Dec; 2(12):1343-51. PubMed ID: 6096517 [TBL] [Abstract][Full Text] [Related]
18. Late intensification in small-cell lung cancer: a phase I study of high doses of cyclophosphamide and etoposide with autologous bone marrow transplantation. Sculier JP; Klastersky J; Stryckmans P J Clin Oncol; 1985 Feb; 3(2):184-91. PubMed ID: 2981983 [TBL] [Abstract][Full Text] [Related]
19. VP 16-213 and cyclophosphamide in the treatment of refractory acute nonlymphocytic leukemia with monocytic features. Hurd DD; Peterson BA; McKenna RW; Bloomfield CD Med Pediatr Oncol; 1981; 9(3):251-5. PubMed ID: 7017368 [TBL] [Abstract][Full Text] [Related]
20. A combination of cyclophosphamide, methotrexate, vincristine and VP 16-213 (NSC 141 540) in the treatment of bronchogenic carcinoma. Cavalli F; Hasler E; Ryssel HJ; Sonntag RW; Brunner KW Tumori; 1977; 63(2):169-73. PubMed ID: 898287 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]